RT Journal Article
SR Electronic
T1 Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 893
OP 902
DO 10.21873/anticanres.15547
VO 42
IS 2
A1 TODAKA, AKIKO
A1 NARA, SATOSHI
A1 MOTOI, FUYUHIKO
A1 MORINAGA, SOICHIRO
A1 TOSHIYAMA, REISHI
A1 HIGUCHI, RYOTA
A1 KONISHI, MASARU
A1 SHIRAKAWA, HIROFUMI
A1 TSUMURA, HIDETAKA
A1 OKUYAMA, HIROYUKI
A1 NAGANO, HIROAKI
A1 SHIOJI, KAZUHIKO
A1 SUGIMACHI, KEISHI
A1 ASAGI, AKINORI
A1 MIZUNO, NOBUMASA
A1 FURUSE, JUNJI
YR 2022
UL http://ar.iiarjournals.org/content/42/2/893.abstract
AB Background/Aim: We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy. Patients and Methods: The clinicopathological data of patients with pancreatic adenocarcinoma with CY1 at 14 institutions, between 2007 and 2015, were collected and analyzed. Results: Of the 124 eligible patients, 114 underwent macroscopically curative resection. Of the 114 patients, 80 (70%) did not have early recurrence and received postoperative chemotherapy that was S-1 in 43 (54%), gemcitabine in 31 (39%), and others in six (7%). The median overall survival was 21.0 months in S-1 and 19.2 in gemcitabine therapy (p=0.23), whereas the median relapse-free survival was 10.2 and 7.1 months (p=0.03), respectively. Conclusion: Following the change in adjuvant therapy, most PC patients with CY1 who underwent macroscopically curative resection received S-1; however, it was insufficient. Further development of postoperative chemotherapy is required.